ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novartis has received FDA approval for Coartem, the first artemisinin-based combination treatment for malaria to be approved in the U.S. In conjunction with the approval, Novartis also wins the first priority review voucher (PRV), a coupon good for expediting the review of any other New Drug Application. PRVs are only awarded with the approval of novel drugs for neglected diseases and can be sold to another firm. FDA introduced the vouchers in 2007 to entice companies to devote research dollars to diseases that primarily affect developing countries (C&EN, Jan. 19, page 38).
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter